A critical review of pharmacotherapy for major depressive disorder

International Journal of Neuropsychopharmacology

Volumn 14, Issue 10, 2011, Pages 1417-1431

  Dupuy, Jamie M ^a   Ostacher, Michael J ^b   Huffman, Jeffrey ^a   Perlis, Roy H ^a   Nierenberg, Andrew A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; major depressive disorder; outcomes; pharmacological treatment

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; KETAMINE; LAMOTRIGINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; MODAFINIL; PAROXETINE; PRAMIPEXOLE; REBOXETINE; RILUZOLE; S ADENOSYLMETHIONINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL ASSESSMENT; CLINICAL PROTOCOL; COMPULSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR DEPRESSION; MANIA; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NEUROLEPTIC MALIGNANT SYNDROME; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SUICIDE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG COSTS; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SELECTION; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 80054988293     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000083     Document Type: Review

References (91)

1. Abraham G, Milev R, Stuart Lawson J (2006). T3 augmentation of SSRI resistant depression. Journal of Affective Disorders 91, 211-215.
2. Aiken CB (2007). Pramipexole in psychiatry : A systematic review of the literature. Journal of Clinical Psychiatry 68, 1230-1236. (Pubitemid 47395626)
3. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, et al. (2001). Does thyroid SUPPL.ementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. American Journal of Psychiatry 158, 1617-1622. (Pubitemid 32923653)
4. Anderson IM (1998). SSRIs vs. tricyclic antidepressants in depressed inpatients : A meta-analysis of efficacy and tolerability. Depression and Anxiety 7 (SUPPL. 1), 11-17.
5. Anderson IM (2000). Selective serotonin reuptake inhibitors vs. tricyclic antidepressants : A meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58, 19-36. (Pubitemid 30173208)
6. Angst J, Gamma A, Sellaro R, Lavori PW, et al. (2003). Recurrence of bipolar disorders and major depression. A life-long perspective. European Archives of Psychiatry and Clinical Neuroscience 253, 236-240. (Pubitemid 37203960)
7. Ballon JS, Feifel D (2006). A systematic review of modafinil : Potential clinical uses and mechanisms of action. Journal of Clinical Psychiatry 67, 554-566. (Pubitemid 43764232)
8. Barbosa L, Berk M, Vorster M (2003). A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of Clinical Psychiatry 64, 403-407. (Pubitemid 36547282)
9. Barbui C, Hotopf M, Freemantle N, Boynton J, et al. (2003). Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) vs. tricyclic antidepressants (TCAs). Cochrane Database of Systematic Reviews. Issue 3, Art. No. CD002791.
10. Carpenter LL, Yasmin S, Price LH (2002). A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biological Psychiatry 51, 183-188. (Pubitemid 34127908)
11. Cipriani A, Furukawa TA, Salanti G, Geddes JR, et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants : A multiple-treatments meta-analysis. Lancet 373, 746-758.
12. Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics : A systematic review of one-year studies. American Journal of Psychiatry 161, 414-415.
13. Corrigan MH, Denahan AQ Wright CE, Ragual RJ, et al. (2000). Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety 11, 58-65. (Pubitemid 30228411)
14. Coryell W, Endicott J, Keller MB (1991). Predictors of relapse into major depressive disorder in a nonclinical population. American Journal of Psychiatry 148, 1353-1358.
15. Crossley NA, Bauer M (2007). Acceleration and augmentation of antidepressants with lithium for depressive disorders : two meta-analyses of randomized, placebo-controlled trials. Journal of Clinical Psychiatry 68, 935-940. (Pubitemid 47015495)
16. DeBattista C, Doghramji K, Menza MA, Rosenthal MH, et al. (2003). Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder : A preliminary double-blind, placebo-controlled study. Journal of Clinical Psychiatry 64, 1057-1064. (Pubitemid 37158251)
17. DeBattista C, Hawkins J (2009). Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 23, 369-377.
18. DeBattista C, Lembke A, Solvason HB, Ghebremichael R, et al. (2004). A prospective trial of modafinil as an adjunctive treatment of major depression. Journal of Clinical Psychopharmacology 24, 87-90. (Pubitemid 38134171)
19. Elgamal S, MacQueen G (2008). Galantamine as an adjunctive treatment in major depression. Journal of Clinical Psychopharmacology 28, 357-359.
20. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, et al. (2006). A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients : A STAR D report. American Journal of Psychiatry 163, 1161-1172. (Pubitemid 44464443)
21. Fava M, Thase ME, DeBattista C (2005). A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. Journal of Clinical Psychiatry 66, 85-93.
22. Fergusson D, Doucette S, Cranley Glass K, Shapiro S, et al. (2005). Association between suicide attempts and selective serotonin reuptake inhibitors : systematic review of randomized controlled trials. British Medical Journal 330, 396.
23. Fochtman LJ, Gelenberg AJ (2005). Guideline Watch: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 2nd edn. American Psychiatric Association (http://www.psychiatryonline.com/pracGuide/ loadGuidelinePdf.aspx?file=MDD.watch). Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, et al. (2010). Antidepressant drug effects and depression severity : A patient-level meta-analysis. Journal of the American Medical Association 303, 47-53.
24. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, et al. (2008). Comparative benefits and harms of secondgeneration antidepressants : background paper for the American College of Physicians. Annals of Internal Medicine 149, 734-750.
25. Geddes JR, Carney SM, Davies C, Furukawa TA, et al. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders : A systematic review. Lancet 361, 653-661. (Pubitemid 36246547)
26. Geddes JR, Freemantle N, Mason J, Eccles MP, et al. (2002). Selective serotonin reuptake inhibitors (SSRIs) for depression. Cochrane Database of Systematic Reviews. Issue 2, Art. No. CD00185.
27. Gibbons RD, Brown CH, Hur K, Marcus SM, et al. (2007). Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry 164, 1356-1363. (Pubitemid 47461135)
28. Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2005). The relationship between antidepressant medication use and rate of suicide. Archives of General Psychiatry 62, 165-172. (Pubitemid 40189132)
29. Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2006). The relationship between antidepressant prescription rates and rate of early adolescent suicide. American Journal of Psychiatry 163, 1898-1904. (Pubitemid 44807781)
30. Goodwin GM, Emsley R, Rembry S, Rouillon F, et al. (2009). Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome : A 24-week randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry 70, 1128-1137.
31. Guaiana G, Barbui C, Hotopf M (2007). Amitriptyline for depression. Cochrane Database of Systematic Reviews 3, CD004186.
32. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ (2007). Lithium treatment reduces suicide risk in recurrent major depressive disorder. Journal of Clinical Psychiatry 68, 380-383. (Pubitemid 46506801)
33. Hansen R, Gaynes B, Thieda P, Gartlehner G, et al. (2008). Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatric Services 59, 1121-1130.
34. Hardy M, Coulter I, Morton SC, Favreau J, et al. (2002). S-adenosyl-methionine for treatment of depression, osteoarthritis, and liver disease (publication number, 02-E04). Rockville, MD, Agency for Healthcare Research and Quality, US Department of Health and Human Services. Hashimoto K (2009). Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Research Reviews 61, 105-123.
35. Holtzheimer 3rd PE, Meeks TW, Kelley ME,Mufti M, et al. (2008). A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. International Journal of Geriatric Psychiatry 23, 625-631. (Pubitemid 351943848)
36. Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, et al. (2005). An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 66, 1038-1042. (Pubitemid 41191797)
37. Judd L, Akiskal HS, Maser JD, Zeller PJ, et al. (1998). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Journal of Affective Disorders 50, 97-108. (Pubitemid 28551779)
38. Keller MB, Lavori PW, Lewis CE, Klerman GL (1983). Predictors of relapse in major depressive disorder. Journal of the American Medical Association 250, 3299-3304. (Pubitemid 14217770)
39. Kennedy N, Paykel ES2004). Residual symptoms at remission from depression: impact on long-term outcome. Journal of Affective Disorders 80, 135-144. (Pubitemid 38597136)
40. Kennedy SH, Rizvi S, Fulton K, Rasmussen J (2008). A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of Clinical Psychopharmacology 28, 329-333.
41. Kessler RC, Berglund P, Demler O, Jin R, et al. (2003). The epidemiology of major depressive disorder : results from the National Comorbidity Survey Replication (NCS-R). Journal of the American Medical Association 289, 3095-3105. (Pubitemid 37432885)
42. Khan A, Leventhal RM, Khan SR, Brown WA (2002). Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 22, 40-45. (Pubitemid 34101291)
43. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, et al. (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine/Public Library of Science 5 e45.
44. Lauterbach E, Felber W, Muller-Oerlinghausen B, Ahrens B, et al. (2008). Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders : A randomised, placebo-controlled, 1-year trial. Acta Psychiatrica Scandinavica 118, 469-479.
45. Leon AC (2007). The revised warning for antidepressants and suicidality : unveiling the black box of statistical analyses. American Journal of Psychiatry 164, 1786-1789. (Pubitemid 351739229)
46. Leon AC, Solomon DA, Mueller TI, Endicott J, et al. (2003). A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. American Journal of Psychiatry 160, 727-733. (Pubitemid 41079606)
47. MajM, Veltro F, Pirozzi R, Lobrace S, et al. (1992). Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. American Journal of Psychiatry 149, 795-800.
48. McGrath PJ, Khan AY, Trivedi MH, Stewart JW, et al. (2008). Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features : A STAR D report. Journal of Clinical Psychiatry 69, 1847-1855.
49. McGrath PJ, Stewart JW, Fava M, Trivedi MH, et al. (2006). Tranylcypromine vs. venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR D report. American Journal of Psychiatry 163, 1531-1541. (Pubitemid 44465752)
50. McMahon FJ, Buervenich S, Charney D, Lipsky R, et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics 78, 804-814.
51. Montejo AL, Prieto N, Terleira A, Matias J, et al. (2010). Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. Journal of Psychopharmacology 24, 111-120.
52. Mueller TI, Leon AC, Keller MB, Solomon DA, et al. (1999). Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. American Journal of Psychiatry 156, 1000-1006. (Pubitemid 29302790)
53. Mulder RT, Joyce PR, Frampton CM, Luty SE, et al. (2008). Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. Acta Psychiatrica Scandinavica 118, 116-122. (Pubitemid 351962156)
54. Nakagawa A, Grunebaum MF, Ellis SP, OquendoMA, et al. (2007). Association of suicide and antidepressant prescription rates in Japan, 1999-2003. Journal of Clinical Psychiatry 68, 908-916. (Pubitemid 47015491)
55. Nelson JC, Papakostas GI (2009). Atypical antipsychotic augmentation in major depressive disorder : A meta-analysis of placebo-controlled randomized trials. American Journal of Psychiatry 166, 980-991.
56. Nierenberg AA, Amsterdam JD (1990). Treatment-resistant depression: definition and treatment approaches. Journal of Clinical Psychiatry 51 (SUPPL.), 39-47. (Pubitemid 20212863)
57. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, et al. (2000). Timing of onset of antidepressant response with fluoxetine treatment. American Journal of Psychiatry 157, 1423-1428.
58. Nierenberg AA, Husain MM, Trivedi MH, Fava M, et al. (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse : A STAR D report. Psychological Medicine 40, 41-50.
59. Nierenberg AA, Papakostas GI, Petersen T, Montoya HD, et al. (2003). Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. Journal of Clinical Psychopharmacology 23, 92-95. (Pubitemid 36164430)
60. Papakostas GI (2009). The role of S-adenosyl methionine in the treatment of depression. Journal of Clinical Psychiatry 70 (SUPPL. 5), 18-22.
61. Papakostas GI, Homberger CH, Fava M (2008). A metaanalysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Journal of Psychopharmacology 22, 843-848.
62. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, et al. (2010). S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder : A double-blind, randomized clinical trial. American Journal of Psychiatry 167, 942-948.
63. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, et al. (2006). A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. Journal of Clinical Psychopharmacology 26, 56-60. (Pubitemid 43167092)
64. Papakostas GI, Peterson T, Sklarsky KG, Nierenberg AA, et al. (2007b). Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Research 149, 195-200. (Pubitemid 46108106)
65. Papakostas GI, Thase ME, Fava M, Nelson JC, et al. (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biological Psychiatry 62, 1217-1227. (Pubitemid 350060895)
66. Perlis RH, Moorjani P, Fagerness J, Purcell S, et al. (2008). Pharmacogenetic analysis of genes implicated in rodent modesls of antidepressant response: association of TREK 1 and treatment resistance in the STAR()D study. Neuropsychopharmacology 33, 2810-2819.
67. Perlis RH, Patrick A, Smoller JW, Wang PS (2009). When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR D study. Neuropsychopharmacology 34, 2227-2236.
68. Pintor L, Gasto C, Navarro V, Torres X, et al. (2003). Relapse of major depression after complete and partial remission during a 2-year follow-up. Journal of Affective Disorders 73, 237-244. (Pubitemid 36120734)
69. Posternak M, Novak S, Stern R, Nennessey J, et al. (2008). A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. International Journal of Neuropsychopharmcology 11, 15-25.
70. Rasmussen NA, Schroder P, Olsen LR, Brodsgaard M, et al. (2005). Modafinil augmentation in depressed patients with partial response to antidepressants : A pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptoms Checklist (SCL-92). Nordic Journal of Psychiatry 59, 173-178. (Pubitemid 40946275)
71. Roy-Byrne P, Post RM, Uhde TW, Porcu T, et al. (1985). The longitudinal course of recurrent affective illness : life chart data from research patients at the NIMH. Acta Psychiatrica Scandinavica (SUPPL.) 7, 3-34.
72. Ruhe HG, Huyser J, Swinkels JA, Schene AH (2006). Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder : A systematic review. Journal of Clinical Psychiatry 67, 1836-1855. (Pubitemid 46055194)
73. Rush AJ, Trivedi MH,Wisniewski SR, Nierenberg AA, et al. (2006a). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : A STAR D report. American Journal of Psychiatry 163, 1905-1917. (Pubitemid 44807782)
74. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, et al. (2006b). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354, 1231-1242.
75. Rush AJ, Wisniewski SR, Warden D, Luther JF, et al. (2008). Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Archives of General Psychiatry 65, 870-880.
76. Sanacora G (2009). Do glutamatergic agents represent a new class of antidepressant drugs? Part 1. Journal of Clinical Psychiatry 70, 1473-1474.
77. Schindler F, Anghelescu IG (2007). Lithium vs. lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. International Clinical Psychopharmacology 22, 179-182. (Pubitemid 46559875)
78. Serretti A, Kato M, De Ronchi D, Kinoshita T (2007). Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry 12, 247-257. (Pubitemid 46328503)
79. Simpson HB, Nee JC, Endicott J (1997). First-episode major depression: few sex differences in course. Archives of General Psychiatry 54, 633-639. (Pubitemid 27306573)
80. Solomon DA, Keller MB, Leon AC, Mueller TI, et al. (2000). Multiple recurrences of major depressive disorder. American Journal of Psychiatry 157, 229-233. (Pubitemid 30080902)
81. Stahl SM, Fava M, Trivedi MH, Caputo A, et al. (2010). Agomelatine in the treatment of major depressive disorder : an 8-week, multicenter, randomized, placebo-controlled trial. Journal of Clinical Psychiatry 71, 616-626.
82. Trivedi MH, Fava M, Wisniewski SR, Thase ME (2006). Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 354, 1243-1252.
83. Uher R, Huezo-Diaz P, Perroud N, Smith R, et al. (2009). Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics Journal 4, 225-233.
84. Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ (2005). Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 19, 137-146.
85. Wade AG, Schlaepfer TE, Andersen HF, Kilts CD (2009). Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). Journal of Psychiatric Research 43, 568-575.
86. Weihs KL, Houser T, Batey SR, Ascher JA, et al. (2002). Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biological Psychiatry 51, 753-761. (Pubitemid 34450811)
87. Wilson K, Mottram P, Sivanranthan A, Nightingale A (2003). Antidepressants vs. placebo for the depressed elderly. Cochrane Database of Systematic Reviews. Issue 2, Art. No. CD000561.
88. Zajecka J, Schatzberg A, Stahl S, Shah A, et al. (2010). Efficacy and safety of agomelatine in the treatment of major depressive disorder : A multicenter, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 30, 135-144.
89. Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, et al. (2006a). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63, 856-864.
90. Zarate CA, Singh JB, Quiroz JA, De Jesus G, et al. (2006b). A double-blind, placebo-controlled study of memantine in the treatment of major depression. American Journal of Psychiatry 163, 153-155. (Pubitemid 43050119)
91. Zimmerman M, Posternak MA, Chelminski I (2002). Symptom severity and exclusion from antidepressant efficacy trials. Journal of Clinical Psychopharmacology 22, 610-614. (Pubitemid 35416787)